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been treated with PAP-1 (6 mg kg1,
0.2 ml injection volume per graft)
showed complete hair regrowth
(Figure 2a, e) and complete histological
(Figure 2f) and immunohistological
normalization of the skin phenotype
(Figure 2g). In addition, quantitative
immunohistomorphometry revealed that
the number of Kv1.3þ /CD3þ cells
was significantly reduced in the respon-
der grafts (Figure 1d), compared with
either phosphate-buffered saline (PBS)-
treated control grafts or nonresponder
grafts (Figure 1e). Interestingly, Kv1.3
blockade by PAP-1 significantly reduced
the number of perifollicular and intra-
follicular Kv1.3þ cells even in the three
nonresponder grafts, as compared
with PBS-treated control AA lesions
(Figure 1e). As the cellular infiltrate in
spontaneously developed human AA
lesions and in the injected grafts that
developed AA lesions strongly expres-
sed Kv1.3, it is reasonable to assume
that the therapeutic effect of PAP-1
and its reduction of the number of
NKG2Dþ /CD56þ cells were owing
to its Kv1.3-blocking effects.
Taken together, these pilot data sug-
gest that Kv1.3þ /CCR7 TEM cells may
be both important elements in human
AA pathogenesis and promising targets
for more selective future immuno-
therapy of AA. Evidently, the robustness
of anti-AA effects of Kv1.3 blockers
needs to be confirmed in larger cohorts
of humanized AA mice (Gilhar et al.,
2013). However, the limited currently
available data are in line with promising
results obtained with Kv1.3 blockers
in other autoimmune disease (s10, s4;
Wulff et al., 2003b, 2009, Beeton
et al., 2006) and psoriasis models
(Gilhar et al., 2011). This encourages
one to systematically explore Kv1.3 block-
ade as a therapeutic strategy in human
AA (for additional background, methods,
discussion, and supplementary references,
see Supplementary Text online).
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TO THE EDITOR
Acne is a multifactorial disease of
the pilosebaceous unit resulting from
increased sebum production, altered
keratinization, inflammation, and bac-
terial hypercolonization. With respect to
hyperseborrhea as one of the contribut-
ing factors, it is of interest to study
pathways that regulate sebaceous
gland differentiation. Interestingly,
mouse strains deficient in the enzyme
stearoyl-CoA desaturase 1 (SCD1) exhi-
bit severe hypoplasia of sebaceousAccepted article preview online 27 February 2013; published online 4 April 2013
Abbreviation: SCD, stearoyl-CoA desaturase
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glands (Zheng et al., 1999; Sundberg
et al., 2000; Miyazaki et al., 2001;
Georgel et al., 2005). SCDs are micro-
somal enzymes that catalyze the bio-
synthesis of monounsaturated fatty acids
from saturated acyl-CoAs (Ntambi
and Miyazaki, 2003); specifically they
introduce cis-double bonds in the D9
position, the preferred substrates being
palmitoyl-CoA and stearoyl-CoA. Here,
we asked whether pharmacological
inhibition of SCD activity would have
an impact on sebaceous glands.
From a series of novel SCD1
inhibitors (Zhang et al., 2013),
compound XEN103, (6-[4-(5-fluoro-2-
trifluoromethylbenzoyl)-piperazin-1-yl]
pyridazine-3-carboxylic acid (2-cyclo
propylethyl)amide (Figure 1a), was
chosen for further characterization.
XEN103 inhibited SCD1 activity in
mouse liver microsomes with IC50¼14
nM. The compound featured 700-fold
selectivity for mouse SCD1 activity
relative to the closely related D5- and
D6-desaturases (FADS1 and FADS2),
indicating low potential for blockade
of essential fatty acid and sapienic acid
biosynthesis, in which these enzymes
are involved.
In human HepG2 cells, XEN103
blocked SCD1 activity with IC50¼ 12nM.
Furthermore, XEN103 treatment of
human SZ95 sebocytes led to reduction
of monounsaturated acyl chains in
phosphatidylcholine with IC50¼ 11 nM
(Figure 1b); these cells express SCD1
(Harrison et al., 2007) but not SCD5
(our unpublished data), the only other
known human D9-desaturase.
Expression of SCD1 in SZ95 cells is
increased by treatment with testosterone
and linoleic acid; this increase was
shown previously to be blocked by
XEN103 using a semiquantitative
method (Zouboulis et al., 2011).
Quantitative reverse transcriptase–PCR
showed half-maximal inhibition
between 10 and 100 nM XEN103
(Figure 1c). Thus, XEN103 not only acts
as an enzyme inhibitor but also blocks
androgen-induced transcription of the
gene. One may speculate that a product
of SCD1 required for SCD1 transcription
is involved in a positive feedback loop.
We assessed the effect of XEN103 on
mouse skin after topical application.
Mice were treated for 8 days on the
shaved back with solutions containing
0.1% or 1% XEN103 in propylene
glycol/ethanol 7:3, to assess local toler-
ance and activity. There were no signs
of skin irritation at the test sites during
the treatment period visible by macro-
scopic inspection or by histological
examination. As assessed by histomor-
phometry, application of 1% XEN103
reduced the numbers of sebaceous
glands byB65% (Po0.001) and the size
of the remaining glands byB50%
(Po0.01) (Figure 2a). In a total of three
independent studies, reduction of sebac-
eous gland numbers and size varied in
the range of 50–75%. Representative
photographs of vehicle- and XEN103-
treated skin samples stained with
hematoxylin–eosin or with oil red O
are shown in Figure 2b and c, respec-
tively. While numerous normally sized
and lipid-loaded sebaceous glands were
seen at vehicle-treated sites, only very
small atrophic sebaceous glands with
hardly any associated lipid staining
were visible at XEN103-treated sites.
Thus, the SCD1 inhibitor XEN103
clearly induces an atrophogenic effect
on the sebaceous glands in mouse skin,
which should consequently result in
reduced sebum lipids.
When XEN103 was applied in
solution at a concentration of 0.1%,
XEN103 induced little atrophogenic
effect (Figure 2a); in a separate study
we determined the minimal effective
concentration to 0.5% (data not shown).
While a trend toward a decrease in
sebaceous gland size was already
observed after 2 days, the effect
increased with time and was statistically
significant after 6 days for both size and
numbers (Figure 2d). When treatment
was stopped after 7 days, sebaceous
gland numbers and size reverted
to normal values within 2 weeks (data
not shown).
At skin areas distant from the
XEN103-treated sites, there was no
significant reduction in the number of
sebaceous glands (Figure 2a). This indi-
cates that efficacy is restricted to the
topically treated area, excluding activity
at distant sites due to percutaneous
absorption. This observation is in line
with the observed low plasma exposure
with XEN103, while at least 1000-fold
higher concentrations of XEN103
were found in the skin (Supplementary
Table S1 online).
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Figure 1. XEN103 blocks fatty acid desaturation and stearoyl-CoA desaturase (SCD-1) expression in
human sebocytes. (a) Chemical structure of XEN103. (b) Human SZ95 sebocytes were treated with
XEN103 for 72 hours, followed by extraction of lipids and determination of the desaturation index by liquid
chromatography-mass spectroscopy analysis. Bars represent mean values from four determinations; error
bars represent standard deviation from the mean. Statistical significance with Po0.001 was observed for all
groups treated with XEN103 versus the untreated control. (c) Cells were incubated for 48 hours with
XEN103 or with dimethylsulfoxide as solvent control in the presence or absence of testosterone (20 nM)
plus linoleic acid (100mM). Total RNA was isolated from the cells, and levels of Scd-1 messenger RNA were
quantified by quantitative reverse transcriptase–PCR. *Po0.05; **Po0.01 versus control.
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To determine whether topical appli-
cation of XEN103 indeed blocked SCD
activity in the skin, we determined the
ratio of palmitoleic and palmitic acid as
a measure of D9-desaturase activity.
The desaturation of fatty acids in the
triglycerides was reduced by about
50% when mice were treated with 1%
XEN103 (Figure 2e). In the 0.1%
XEN103-treated group, reduction was
by 20%. This result correlates well with
the sebaceous glands’ atrophy end point
and the skin exposure to XEN103.
To summarize, XEN103 is a potent
inhibitor of SCD activity as shown in
microsomal preparations, cultured cells,
and in rodents in vivo. The compound is
active on its target enzyme across
species and, importantly, it also reduces
both the activity and the androgen-
induced expression of SCD1 in human
sebocytes. Using this tool compound,
we show that pharmacological
inhibition of SCD in mouse skin rapidly
induces pronounced sebaceous gland
atrophy after topical application in a
dose- and time-dependent manner. The
effect is due to the local action of the
compound on SCD activity in the skin
and occurs in the presence of only
minimal plasma exposure, thus exclud-
ing any potentially undesirable effects of
systemic SCD inhibition.
In mice, there are three D9-desa-
turases apart from SCD1, namely
SCD2–4, which potentially could be
inhibited by XEN103; however, Scd2-
deficient mice have normal sebaceous
glands (Miyazaki et al., 2005), the
Scd3 gene cannot compensate Scd1
deficiency in asebia mice (Zheng
et al., 2001), and Scd4 expression is
restricted to the heart (Miyazaki et al.,
2003). Thus, we consider that sebaceous
gland atrophy in mouse skin is most
likely due to inhibition of SCD1.
In human skin, SCD1 is present as the
only D9-desaturase. It will be interesting
to learn from a clinical study whether an
SCD1 inhibitor such as XEN103 also
induces human sebaceous gland
atrophy when applied in a topical
formulation allowing for adequate expo-
sure at the target.
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Figure 2. Topical XEN103 induces sebaceous gland atrophy. (a) Compound solutions were applied to the back of NMRI mice for 8 days twice daily. The number
and size of sebaceous glands was determined by histomorphometry on day 9. (b) Photomicrographs of hematoxylin–eosin–stained skin sections. Upper: overview
(100 ), sebaceous glands indicated by the arrow; lower: magnification (400 ) of indicated glands. Bar¼ 100mm. (c) Photomicrograph of oil red O–stained
cryosections (200 ). Bar¼ 100mm. (d) Dependence on treatment period. (e) Reduction of C16 desaturation in the skin of mice treated with XEN103 for 8 days;
the skin was analyzed for the ratio of C16:1/C16:0 fatty acids in the triglyceride fraction of lipids by liquid chromatography-mass spectroscopy. In the graphs, bars
represent mean values of 4–5 animals; error bars represent standard deviation; *Po0.05; **Po0.01, ***Po0.001 versus vehicle.
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TO THE EDITOR
Hair is produced by a specialized skin
appendage comprising the pilose-
baceous unit and associated structures.
Hair growth, tightly regulated by growth
factors, cytokines, neuropeptides, hor-
mones, and environmental cues, is not
a continual process and cyclical hair
follicle renewal requires activation of
local reservoirs of stem cells. Seminal
work in mice localized a reservoir of
slow cycling, epithelial stem cells in
the bulge, a distinct segment of the
outer root sheath (ORS) of mouse folli-
cles (Cotsarelis et al., 1990). It is now
known that the follicle is endowed with
numerous stem cell reservoirs, including
a Lgr5þ , actively cycling cell popula-
tion in the lower ORS (Jaks et al., 2008),
and that these reservoirs express
different markers and seem to have
different functions (Jaks et al., 2010).
With respect to human hair follicles,
early work suggested the existence of
at least two pools of pluripotent cells
(Lenoir et al., 1988). In accordance with
these findings, high b1-integrin (CD29)
expression, which has been associated
with epithelial stem cells (Jones and
Watt, 1993), is observed in sections of
both the upper and lower ORS (Commo
and Bernard, 1997). In addition, keratin
19 (K19) labeling clearly identifies two
groups of putative stem cells in the hair
follicle. Although upper ORS K19þ
cells are negative for the proliferation
marker Ki67, some lower ORS K19þ
cells are Ki67þ suggesting that, as in
mouse follicles, both quiescent and
active stem cells are present in human
hair follicles (Commo et al., 2000). The
upper and lower reservoirs of K19þ
cells are not, however, identical and can
be distinguished by differential expres-
sion of K15 and CD200, more highly
expressed in the upper reservoir, and
CD271, CD29, and CD34, more highly
expressed in the lower reservoir (Inoue
et al., 2009). This differential epitope
mapping appears to not be restricted
to the ORS as the connective tissue
sheath (CTS) in conjunction with these
two reservoirs also harbors distinct
compartments. For example, one
chondroitin sulfate epitope (4C3-CS) is
specific for the upper CTS while another
chondroitin sulfate epitope (7D4-CS)
and N-sulfated D-glucuronic acid-rich
heparin sulfate (HepSS-1 epitope) are
only observed in the lower CTS
(Malgouries et al., 2008). In summary,
the human hair follicle can be charac-
terized by the presence of at least two
epithelial stem cell reservoirs that interact
with specific microenvironments.
Considering the essential role of the
niche in stem cell maintenance and
function, we are interested in micro-
environmental factors that influence
human hair follicle stem cells. The
human hair follicle is considered asAccepted article preview online 8 March 2013; published online 11 April 2013
Abbreviations: CA IX, carbonic anhydrase IX; CTS, connective tissue sheath; GLUT1, glucose transporter 1;
HIF1, hypoxia-inducible transcription factor 1; K19, keratin 19; ORS, outer root sheath
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